Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

PerkinElmer, Inc.. (2/17/16). "Press Release: PerkinElmer Opens New Diagnostics Facility in Chennai". Waltham, MA & Chennai.

Region Region Chennai
  Country India
Organisations Organisation Surendra Genetic Labs Pvt. Ltd.
  Group PerkinElmer (Group)
  Organisation 2 PerkinElmer India Pvt. Ltd.
  Group PerkinElmer (Group)
Products Product diagnostic services
  Product 2 diagnostic test, neonatal
Persons Person Singh, Prahlad (PerkinElmer 201901– COO joined 2014 as President Diagnostics before GE Healthcare + Philips Healthcare)
  Person 2 Thacker, Jayashree (PerkinElmer 201602 President PerkinElmer India)

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, has expanded its footprint in India with the opening of a new diagnostics facility in Chennai, Tamil Nadu. The laboratory will provide a comprehensive menu of diagnostic screening services to hospitals, maternity nursing facilities, diagnostic labs and clinicians throughout India.

Prahlad Singh, President, Diagnostics, PerkinElmer formally inaugurated the facility today in the presence of a leading group of clinicians, including gynecologists, fetal medicine specialists and pediatricians, along with medical research professionals and key opinion leaders.

Since 1981, PerkinElmer has been providing instruments and services to customers in India, spanning a wide range of markets. The opening of the Chennai laboratory broadens PerkinElmer's diagnostic offerings to respond to India's growing need for easier access to technologies that can screen for and help diagnose prenatal and neonatal conditions. Newborn screening helps detect metabolic and other inherited disorders that are treatable only when identified during the first few days of life.

"We are experiencing a steady rise in demand for maternal fetal health and newborn screening solutions in India as hospitals, clinicians and expectant parents strive to ensure healthier outcomes through early detection, diagnosis and proper management of prenatal and neonatal conditions," said Jayashree Thacker, President, PerkinElmer India. "This state-of-the art laboratory underscores our commitment to our continued expansion plans in India. By increasing our capacity to accommodate higher testing volumes, offer a comprehensive and growing menu of diagnostic assays, and provide a hands-on experience with our innovative technologies, we are further supporting India's healthcare requirements."

The Chennai laboratory extends PerkinElmer's capabilities in India with a widened set of assays related to cytogenetics and molecular diagnostics. PerkinElmer will also provide customer service and support, along with product training and demonstrations, at the Chennai laboratory. A newborn screening application facility within the lab will showcase PerkinElmer's programs and includes visual aids, equipment platforms and application software to support key stakeholders.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.

The Company established direct operations in India in 2004 and currently has more than 6,000 customers there across several markets including diagnostics, pharmaceuticals, biotech, food, agriculture, chemicals, plastics, automobile and academic research labs.

PerkinElmer's global diagnostic offerings include: prenatal, neonatal and infectious disease screening, along with molecular diagnostics solutions, through its wide range of instruments, reagents and assay platforms, and software. The Company also provides private cord blood and cord tissue preservation to families through ViaCord, LLC.

Additional information is available through 1-877-PKI-NYSE, or at


Media Contact:
Raghu Basiboina
(t) +91.97.3987.7272

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Record changed: 2019-06-09


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

More documents for PerkinElmer (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Fighting Customers 650x80px

» top